Suchergebnisse - "Cervantes, A"

PubPharm (10)

1

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

enthalten in: ESMO open | 2023

von Rudin, C. | Cervantes, A. | Dowlati, A. | +11

2

Checkpoint inhibitors for gastroesophageal cancers : dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Smyth, E. | Gambardella, V. | Cervantes, A. | +1

CommentIn: Ann Oncol. 2021 Sep;32(9):1189-1190. - PMID 33957223

3

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370) : a multicentre, open-label, phase 3, randomised, controlled trial

enthalten in: The Lancet. Oncology | 2019

von Eng, C. | Kim, T. | Bendell, J. | +77

CommentIn: Lancet Oncol. 2019 Jun;20(6):752-753. - PMID 31003912

4

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6

5

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Sclafani, F. | Roy, A. | Cunningham, D. | +9

6

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2013

von Gonzalez-Martin, A. | Gladieff, L. | Tholander, B. | +62

CommentIn: Eur J Cancer. 2014 Mar;50(4):862-3. - PMID 24418723

7

Current questions for the treatment of advanced gastric cancer

enthalten in: Cancer treatment reviews | 2013

von Cervantes, A. | Roda, D. | Tarazona, N. | +2

8

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab : a TTD group cooperative study

enthalten in: PloS one | 2012

von Díaz-Rubio, E. | Gómez-España, A. | Massutí, B. | +71

9

Cetuximab administered once every second week to patients with metastatic colorectal cancer : a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2010

von Tabernero, J. | Ciardiello, F. | Rivera, F. | +10

10

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy : results of a phase II single institution trial

enthalten in: British journal of cancer | 2008

von Martín-Martorell, P. | Roselló, S. | Rodríguez-Braun, E. | +3

1
[1]